FMP
PolyPid Ltd.
PYPD
NASDAQ
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
3.17 USD
-0.0642 (-2.03%)
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-17.36M
-21.6M
-32.39M
-34.32M
-17.24M
-
-
-
-
-
100
100
100
100
100
100
100
100
100
-879k
-1.18M
-2.99M
-1.77M
-196k
-
-
-
-
-
100
100
100
100
100
-
-
-
-
-18.24M
-22.77M
-35.38M
-36.08M
-17.43M
-
-
-
-
-